63 results about "GDF15" patented technology

Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (PHACTR1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (SPP1), preferentially expressed antigen in melanoma (PRAME), growth differentiation factor 15 (GDF 15), and chemokine C-X-C motif ligand 10 (CXCL10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of PHACTR1, or fragments thereof, either alone or in combination with the detection of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma.

Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.

Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (PHACTR1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (SPP1), preferentially expressed antigen in melanoma (PRAME), growth differentiation factor 15 (GDF15), and chemokine C-X-C motif ligand 10 (CXCL10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of PHACTR1, or fragments thereof, either alone or in combination with the detection of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma.

Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.

The present invention relates to GDF15 as a molecular marker in in vitro assays determining phenotypic stability of articular chondrocytes and predicting the outcome of chondrocyte transplantation.

The present invention relates to a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets, more particularly, a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets comprising the steps of coculturing CD34+ hematopoietic stem cells with stromal cells and adding the compound of Formula 1. Further, the present invention relates to a composition for detecting the differentiation of hematopoietic stem cells into megakaryocytes and platelets, comprising an agent measuring expression level of a gene that is selected from the group consisting of KLF2 (Kiruppel-like factor2), LOC138255 (OTTHUMP00000021439), GDF15 (growth differentiation factor 15) and INHBE (inhibin, betaE), a kit comprising the composition, a method for detecting the differentiation into megakaryocytes and platelets by using the marker genes, a method for regulating the differentiation into megakaryocytes and platelets, and a method for screening a candidate compound that regulates the differentiation into megakaryocytes and platelets.

The invention relates to the field of diagnosis kits, particularly to application of OPN, GDF15, NSE, TRAP5 and OPG to preparation of early liver cancer diagnosis detecting reagents or kits. The invention also discloses a kit which is used for diagnosing early liver cancer in a combined mode by detecting content of OPN, GDF15, NSE, TRAP and OPG in plasma. The kit has the advantages of being high in specificity and sensitivity, can be applied to early diagnosis of liver cancer, therapeutic effect evaluation during treatment and post-treatment metastasis and recurrence monitoring and can provide detecting results earlier than clinical symptoms. The kit and detecting technology is mature, short in cycle and good in specificity.

The invention relates to a GDF15 rapid quantitative fluorescent microsphere detection device and a preparation method thereof, and belongs to the field of medical detection. The device is prepared byadhering a nitrocellulose membrane with a solid phase containing a GDF15 antibody and a goat-anti-mouse IgG polyclonal antibody, glass fiber adsorbed with a fluorescent microsphere labeled GDF15 antibody, a sample pad, absorbent paper and other auxiliary materials. The preparation method comprises the following steps: pretreating a nitrocellulose membrane by adopting a polyethylene glycol glyceroltreatment solution; combining a GDF15 antibody firstly with oleic acid modified zinc sulfide nanoparticles and then adsorbing to a nitrocellulose membrane; and preparing the proper buffer solution and the sample pad treatment solution. The reaction sensitivity is effectively improved on the basis of ensuring complete release of the immunofluorescence microsphere, and under the same threshold value, the dosage of the immunofluorescence microsphere can be reduced, the cost is saved, and the complexity of production operation is not increased. The test paper is high in sensitivity, strong in specificity, simple and convenient to operate, time-saving and strong in practicability.

To obtain data associated with a mitochondrial disease, a method includes measuring the level of at least one protein selected from the group consisting of GDF15 (growth differentiation factor 15), HGF (hepatocyte growth factor), MIG (gamma interferon induction monokine), SCF (stem cell factor) and SCGF-β (stem cell growth factor beta) in a biological sample collected from a subject. The measured protein level is compared to that of control subjects and then it is checked whether or not there is difference between the protein level of the subject and that of control subjects.

The invention discloses a novel use of a novel use of growth-differential factor 15 (GDF15) in assessment of first cerebral stroke of a hypertension patient. The GDF15 is used as a marker for assessment of a first cerebral stroke risk of a subject to be detected. The invention also provides a use of a reagent for detecting a GDF15 level in a detection agent or detection system for assessment of a first cerebral stroke risk of a subject to be detected and also provides a detection system for assessment of a first cerebral stroke risk of a subject to be detected. A hypertension cohort population perspective research proves that the hypertensive patient with a high baseline blood plasma GDF15 level has a high risk of first cerebral stroke and cerebral ischemic stroke.

Methods and systems for diagnosing functional and / or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.

The invention relates to a multi-target detecting method for the early-stage bladder cancer, and belongs to the technical field of biological detection. The multi-target detecting method comprises the following steps of: (1) extracting DNA contained in urea of a patient; (2) carrying out hydrosulphite conversion treatment onto the obtained DNA; (3) detecting seven marker genes including EOMES, GDF15, NID2, PCDH17, POU4F2, TCF21 and ZNF154 by virtue of methylation specific fluorescence quantitative PCR, wherein ALU-C4 is used as a reference gene; (4), judging whether the patient suffers from the early-stage bladder cancer or not according to a CT value in the step (3). The multi-target detecting method disclosed by the invention has the following advantages: a plurality of biomarker genes are adopted for joint detection, and a mode of combining a plurality of markers is applied to improve detecting sensitivity and specificity on the premise of higher specificity of each marker; specific primers are designed according to the plurality of biomarker genes.

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and / or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.

The present invention relates to a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets, more particularly, a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets comprising the steps of coculturing CD34+ hematopoietic stem cells with stromal cells and adding the compound of Formula 1. Further, the present invention relates to a composition for detecting the differentiation of hematopoietic stem cells into megakaryocytes and platelets, comprising an agent measuring expression level of a gene that is selected from the group consisting of KLF2 (Kiruppel-like factor2), LOC138255 (OTTHUMP00000021439), GDF15 (growth differentiation factor 15) and INHBE (inhibin, betaE), a kit comprising the composition, a method for detecting the differentiation into megakaryocytes and platelets by using the marker genes, a method for regulating the differentiation into megakaryocytes and platelets, and a method for screening a candidate compound that regulates the differentiation into megakaryocytes and platelets.

The invention relates to the field of diagnosis kits, particularly to application of OPN, GDF15, NSE, TRAP5 and OPG to preparation of early liver cancer diagnosis detecting reagents or kits. The invention also discloses a kit which is used for diagnosing early liver cancer in a combined mode by detecting content of OPN, GDF15, NSE, TRAP and OPG in plasma. The kit has the advantages of being high in specificity and sensitivity, can be applied to early diagnosis of liver cancer, therapeutic effect evaluation during treatment and post-treatment metastasis and recurrence monitoring and can provide detecting results earlier than clinical symptoms. The kit and detecting technology is mature, short in cycle and good in specificity.

The present invention provides methods for detecting cancers simply and with high precision, and a reagent that can be used for the methods. According to the present invention, a cancer (excluding a castration-resistant prostate cancer) is detected by measuring the intact growth differentiation factor (GDF15) propeptide level, the GDF15 propeptide fragment level, or the total of the intact GDF15 propetide level and the GDF15 propetide fragment level in a sample. The abovementioned methods for detecting cancer include methods for detecting gastric cancer, pancreatic cancer, colorectal cancer, lung cancer, breast cancer or esophageal cancer, or methods for differentiating and detecting non-small cell lung cancer and small cell lung cancer. In addition, antibodies that specifically recognizeGDF15 propeptides are included in a reagent for detecting cancers.